• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

豚鼠胆囊中胆囊收缩素受体拮抗剂、地伐西匹、洛谷胺和洛昔谷胺的联合剂量比分析

Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.

作者信息

Bishop L A, Gerskowitch V P, Hull R A, Shankley N P, Black J W

机构信息

Department of Analytical Pharmacology, King's College School of Medicine & Dentistry, Rayne Institute, London.

出版信息

Br J Pharmacol. 1992 May;106(1):61-6. doi: 10.1111/j.1476-5381.1992.tb14293.x.

DOI:10.1111/j.1476-5381.1992.tb14293.x
PMID:1504732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1907434/
Abstract
  1. Interactions between cholecystokinin octapeptide (CCK-8) and CCKA-receptor antagonists derived from benzodiazepines (devazepide) and glutamic acid (lorglumide and loxiglumide) have been examined in an improved bioassay using the guinea-pig, isolated, gall bladder preparation. 2. The presence of CCKB-receptors in the assay was provisionally-ruled out on the basis of the low potency of pentagastrin in the assay. By applying analyses of both agonism and antagonism, pentagastrin was shown to behave as a partial agonist at the CCKA-receptor. 3. Devazepide, lorglumide and loxiglumide behaved as simple competitive antagonists of CCKA-receptors and pKB values of 9.98, 7.59 and 7.07 were estimated, respectively. 4. Application of a combined dose-ratio analysis to the interactions between CCK-8 and combinations of devazepide/lorglumide and devazepide/loxiglumide indicated that these molecules behave as syntopic, competitive, antagonists at the CCKA-receptor. 5. We conclude that the guinea-pig gall bladder assay contains a homogeneous population of CCKA-receptors and offer an explanation for the differences between our results and those obtained recently by Maubach et al. (1991) which were taken as preliminary evidence for CCKA-receptor heterogeneity.
摘要
  1. 利用豚鼠离体胆囊制备物,通过一种改良的生物测定法研究了八肽胆囊收缩素(CCK - 8)与源自苯二氮䓬类的CCKA受体拮抗剂(地伐西匹)以及谷氨酸类的CCKA受体拮抗剂(洛谷酰胺和洛昔谷酰胺)之间的相互作用。2. 根据该测定法中五肽胃泌素的低效价,初步排除了测定中存在CCKB受体。通过对激动作用和拮抗作用的分析表明,五肽胃泌素在CCKA受体上表现为部分激动剂。3. 地伐西匹、洛谷酰胺和洛昔谷酰胺表现为CCKA受体的简单竞争性拮抗剂,估计其pKB值分别为9.98、7.59和7.07。4. 对CCK - 8与地伐西匹/洛谷酰胺以及地伐西匹/洛昔谷酰胺组合之间的相互作用应用联合剂量比分析表明,这些分子在CCKA受体上表现为同位竞争性拮抗剂。5. 我们得出结论,豚鼠胆囊测定法中含有同质的CCKA受体群体,并对我们的结果与最近Maubach等人(1991年)获得的结果之间的差异做出了解释,后者被视为CCKA受体异质性的初步证据。

相似文献

1
Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.豚鼠胆囊中胆囊收缩素受体拮抗剂、地伐西匹、洛谷胺和洛昔谷胺的联合剂量比分析
Br J Pharmacol. 1992 May;106(1):61-6. doi: 10.1111/j.1476-5381.1992.tb14293.x.
2
The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.利用受体脱敏分析豚鼠胃肌中与收缩相关的CCKA和CCKB/胃泌素受体。
Br J Pharmacol. 1995 Jan;114(2):339-48. doi: 10.1111/j.1476-5381.1995.tb13232.x.
3
Studies of three non-peptide cholecystokinin antagonists (devazepide, lorglumide and loxiglumide) in human isolated alimentary muscle and guinea-pig ileum.三种非肽类胆囊收缩素拮抗剂(地伐西匹、洛谷胺和洛昔谷胺)在人离体消化道肌肉和豚鼠回肠中的研究。
Br J Pharmacol. 1991 Feb;102(2):391-5. doi: 10.1111/j.1476-5381.1991.tb12184.x.
4
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.新型强效选择性CCKA受体拮抗剂T-0632的体外药理学特性
Eur J Pharmacol. 1996 May 23;304(1-3):147-54. doi: 10.1016/0014-2999(96)00091-x.
5
[Effect of cholecystokinin and its antagonists lorglumide, devazepide, and L-365,260 on gastrointestinal motility in rats].
Zhongguo Yao Li Xue Bao. 1993 Sep;14(5):443-6.
6
Characterization of CCK receptors in a novel smooth muscle preparation from the guinea-pig stomach by use of the selective antagonists CI-988, L-365,260 and devazepide.利用选择性拮抗剂CI-988、L-365,260和地伐西匹对豚鼠胃新平滑肌制剂中的胆囊收缩素受体进行表征。
Br J Pharmacol. 1993 Aug;109(4):913-7. doi: 10.1111/j.1476-5381.1993.tb13707.x.
7
CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor.胆囊收缩素拮抗剂表明,胆囊收缩素-8(CCK-8)和JMV-180与大鼠胰腺腺泡细胞CCKA受体上的不同位点相互作用。
Peptides. 1994;15(6):1045-51. doi: 10.1016/0196-9781(94)90069-8.
8
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.新型强效选择性CCKA受体拮抗剂T-0632的体内药理学特性
Eur J Pharmacol. 1996 Sep 26;312(2):227-33. doi: 10.1016/0014-2999(96)00473-6.
9
2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.2-萘磺酰基-L-天冬氨酰-(2-苯乙基)酰胺(2-NAP)——一种选择性胆囊收缩素CCKA受体拮抗剂。
Br J Pharmacol. 1993 Mar;108(3):734-40. doi: 10.1111/j.1476-5381.1993.tb12870.x.
10
Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.基于氯谷胺和L-364,718分子模型的混合型胆囊收缩素-A拮抗剂
J Med Chem. 1992 Mar 20;35(6):1042-9. doi: 10.1021/jm00084a009.

引用本文的文献

1
Control of gallbladder contractions by cholecystokinin through cholecystokinin-A receptors on gallbladder interstitial cells of Cajal.胆囊收缩素通过胆囊Cajal间质细胞上的胆囊收缩素A受体对胆囊收缩进行调控。
World J Gastroenterol. 2008 May 14;14(18):2882-7. doi: 10.3748/wjg.14.2882.
2
Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.人结肠平滑肌中假定的胆囊收缩素(CCK)1受体异质性的药理学证据。
Br J Pharmacol. 2002 Jul;136(6):873-82. doi: 10.1038/sj.bjp.0704794.
3
Mediation by CCKB receptors of the CCK-evoked hyperaemia in rat gastric mucosa.大鼠胃黏膜中胆囊收缩素(CCK)诱发的充血通过CCK B受体介导。
Br J Pharmacol. 1995 Oct;116(4):2274-8. doi: 10.1111/j.1476-5381.1995.tb15064.x.
4
Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.大鼠胃底纵肌中5-羟色胺受体(推定的5-HT2B)的进一步表征
Br J Pharmacol. 1994 May;112(1):323-31. doi: 10.1111/j.1476-5381.1994.tb13072.x.
5
The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.利用受体脱敏分析豚鼠胃肌中与收缩相关的CCKA和CCKB/胃泌素受体。
Br J Pharmacol. 1995 Jan;114(2):339-48. doi: 10.1111/j.1476-5381.1995.tb13232.x.
6
2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.2-萘磺酰基-L-天冬氨酰-(2-苯乙基)酰胺(2-NAP)——一种选择性胆囊收缩素CCKA受体拮抗剂。
Br J Pharmacol. 1993 Mar;108(3):734-40. doi: 10.1111/j.1476-5381.1993.tb12870.x.
7
Application of a model to explore interspecies differences in acetylcholine M-receptor-stimulated gastric acid secretion.应用一种模型来探索乙酰胆碱M受体刺激胃酸分泌的种间差异。
Br J Pharmacol. 1995 Jul;115(6):961-8. doi: 10.1111/j.1476-5381.1995.tb15904.x.

本文引用的文献

1
THE UPTAKE OF ATROPINE AND RELATED DRUGS BY INTESTINAL SMOOTH MUSCLE OF THE GUINEA-PIG IN RELATION TO ACETYLCHOLINE RECEPTORS.豚鼠肠道平滑肌对阿托品及相关药物的摄取与乙酰胆碱受体的关系
Proc R Soc Lond B Biol Sci. 1965 Aug 24;163:1-44. doi: 10.1098/rspb.1965.0058.
2
pH-dependent activity of H1- and H2-histamine receptors in guinea-pig gallbladder.豚鼠胆囊中H1和H2组胺受体的pH依赖性活性
J Pharmacol Exp Ther. 1981 Jun;217(3):638-44.
3
Operational models of pharmacological agonism.药理学激动作用的操作模型。
Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141-62. doi: 10.1098/rspb.1983.0093.
4
The affinity and efficacy of onium salts on the frog rectus abdominis.鎓盐对青蛙腹直肌的亲和力和效能。
Br J Pharmacol Chemother. 1967 Sep;31(1):188-96. doi: 10.1111/j.1476-5381.1967.tb01989.x.
5
The autonomic pharmacology of the bladder.膀胱的自主神经药理学
Annu Rev Pharmacol. 1972;12:197-208. doi: 10.1146/annurev.pa.12.040172.001213.
6
An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.一种药理学激动作用的操作模型:E/[A]曲线形状对激动剂解离常数估计的影响。
Br J Pharmacol. 1985 Feb;84(2):561-71. doi: 10.1111/j.1476-5381.1985.tb12941.x.
7
Evidence that cholecystokinin octapeptide (CCK-8) acts as a potent, full agonist on gastrin receptors for acid secretion in the isolated mouse stomach: lack of antagonism by the specific CCK antagonist asperlicin.胆囊收缩素八肽(CCK - 8)对分离的小鼠胃中胃酸分泌的胃泌素受体起强效、完全激动剂作用的证据:特异性CCK拮抗剂天冬酰胺菌素无拮抗作用。
Digestion. 1986;35(3):170-4. doi: 10.1159/000199363.
8
Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonist.一种新型强效特异性非肽类胆囊收缩素拮抗剂的药理学特性
Arzneimittelforschung. 1987 Jun;37(6):703-7.
9
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.作为新型胆囊收缩素拮抗剂一类成员的氯谷胺的药理特性。
Arzneimittelforschung. 1987 Nov;37(11):1265-8.
10
Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.肽激素胆囊收缩素强效、口服有效的非肽类拮抗剂的设计。
Proc Natl Acad Sci U S A. 1986 Jul;83(13):4918-22. doi: 10.1073/pnas.83.13.4918.